Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the effect of intravenous infusion of autologous bone marrow mononuclear cells (BMMNC) on brain structure and neurocognitive/functional outcomes after severe traumatic brain (TBI) injury in adults. The primary objective is to determine if the intravenous infusion of autologous BMMNC after severe TBI results in structural preservation of global gray matter (GM) volume and white matter (WM) volume and integrity; as well as select regions of interest in the corpus callosum. THe secondary objectives are to determine if autologous BMMNC infusion improves functional and neurocognitive deficits in adults after TBI; reduces the neuroinflammatory response to TBI; evaluate spleen size and splenic blood flow over time using ultrasound and corresponding changes in inflammatory cytokines; and infusion related toxicity and long-term follow-up safety evaluations.

Clinical Trial Description

Traumatic brain injuries are associated with 33% of all trauma related deaths. There are no effective therapies to treat secondary brain injury and the post-injury response of CNS apoptosis and neuroinflammation. Pre-clinical and Phase I clinical progenitor cell therapies have shown promise in TBI/stroke via (1) promotion of CNS structural preservation, and (2) reducing the neuroinflammatory response to injury.

This is a randomized, blinded, Bayesian CRM dose-escalation placebo-controlled study designed to treat severe, acute TBI in adult patients with an IV infusion of autologous bone marrow mononuclear cells. 55 adult TBI patients will be randomized to receive a single IV infusion of BMMNs (6 x 10^6 or 9 x 10^6) or placebo.

Study subjects will be consecutive admissions of adults with severe TBI meeting inclusion/exclusion criteria. Adults, ages 18-55 years, hospitalized at Memorial Hermann Hospital (Houston, Texas) for severe TBI (GCS 3-8) will be screened for eligibility. Informed consent, the bone marrow/sham harvest, and stem cell/placebo infusion must take place within 48 hours of the initial injury.

Following consent and baseline procedures, subjects will be randomized in a 3:2 ratio (using permuted blocks and stratified by GCS of 3-4 or 5-8) to autologous BMMNC infusion (n=33) and placebo (n = 22), respectively. Administration will begin with the lowest dose (i.e. 6 x 10^6 cells/kg body weight) with each dose given to cohorts of 3 subjects treated with BMMNC (note: the cohort size refers only to subjects treated with autologous BMMNC). After each cohort of 3 subjects treated with autologous BMMNC infusion (accumulated on average after every 5.5 adults randomized), the dosage for the next cohort of 3 autologous BMMNC-treated subjects will be determined by the CRM based on the findings for all subjects previously treated and the prior probabilities of the likelihood of toxicity assigned by the investigators before starting the study. At all doses, the algorithm is designed to avoid administering doses that will have a p(toxicity) exceeding 0.15.

Subjects will be monitored closely for infusion related toxicity and complications during the first 14 days post-infusion while also receiving the usual standard of care for traumatic brain injury . Safety and outcome assessments will be performed at 1, 6, and 12 months post-injury study visits. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT02525432
Study type Interventional
Source The University of Texas Health Science Center, Houston
Status Enrolling by invitation
Phase Phase 2
Start date November 21, 2016
Completion date December 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03504709 - REsting and Stimulus-based Paradigms to Detect Organized NetworkS and Predict Emergence of Consciousness
Completed NCT02426749 - Treatment and Recovery Monitoring of Post TBI Symptoms N/A
Completed NCT01339702 - The EPIC Project: Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines
Recruiting NCT03727737 - Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI N/A
Recruiting NCT03153397 - Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial) N/A
Not yet recruiting NCT02776488 - Metabolic Therapy for Traumatic Brain Injury Phase 1/Phase 2
Recruiting NCT02004080 - CREACTIVE - Collaborative REsearch on ACute Traumatic Brain Injury in intensiVe Care Medicine in Europe
Completed NCT01336413 - Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans Phase 2
Recruiting NCT03671083 - Validation of Brain Function Assessment Algorithm for mTBI From Initial Injury to Rehabilitation
Enrolling by invitation NCT02652598 - Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD Phase 2
Recruiting NCT03648476 - Intervention to Change Attributions That Are Negative (ICAN) N/A
Recruiting NCT03089749 - Characterization of Human Autoantibody Titers After Central Nervous System Insult
Active, not recruiting NCT02158494 - Noninvasive Neuromodulation for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury N/A
Active, not recruiting NCT01417468 - How Well do Patients With Traumatic Brain Injury Learn New Material Using Learning Styles in Online Science Classrooms? N/A
Terminated NCT00316004 - Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI) Phase 3
Recruiting NCT02920788 - Mild TBI Assessment & Rehabilitation N/A
Recruiting NCT03068143 - Postoperative Temperature Monitoring In Brain Trauma N/A
Completed NCT00961779 - Safety Study of NNZ-2566 in Healthy Female Subjects Phase 1
Recruiting NCT03515967 - Testing Mild Traumatic Brain Injury (mTBI) in Diverse Athletic Groups N/A
Not yet recruiting NCT03754114 - Brain Oxygen Optimization in Severe TBI, Phase 3 N/A